



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

ALL-BFM Registry

The ALL-BFM Competence Centre at the University Hospital Schleswig-Holstein, Germany, is responsible for the international implementation of the research project (sponsor). The Swiss Paediatric Oncology Group (SPOG) is responsible for the research project in Switzerland (sponsor's representative).

Background

Acute lymphoblastic leukaemia – ALL for short – is the most common form of leukaemia (blood cancer) in childhood and adolescence, accounting for roughly a third of all cancers in this age group. Thanks to intensive research, more than 90% of children and adolescents with ALL can now be permanently cured. The treatment consists of a combination of several drugs that are effective against leukaemia.

Research on ALL includes clinical trials designed to improve the treatment for patients and accompanying research projects. In the research projects, medical data from patients with ALL are analysed.

The ALL-BFM Registry is an international research project including children and adolescents with ALL from various countries. Around 60 patients are expected to take part each year in Switzerland.

Why is this research project needed?

The aim of the ALL-BFM Registry is to collect and evaluate medical data from all young patients with ALL in order to improve the diagnosis and treatment of children and adolescents with ALL. Furthermore, the data will be available for future treatment optimisation studies and research projects.

Although the project participants do not gain personally from taking part in this research project, future patients will reap the benefits: the evaluated data will give researchers new insights into the diagnosis, treatment planning and course of the disease. By doing so, the registry data helps deepen our scientific understanding of ALL, thereby possibly improving the care of children and adolescents with ALL in the future.

Swiss study director: Prof. Jean-Pierre Bourquin MD, PhD, Chief Physician Oncology / Head of the Department of Oncology, Haematology, Immunology, Stem Cell Transplantation and Somatic Gene Therapy, University Children's Hospital Zurich

Deputy study director in Switzerland: Dr. med. Mutlu Kartal-Kaess, Senior Physician, Children's Hospital, Inselspital, University Hospital Berne

Contact details for the sponsor's representative in Switzerland:

SPOG Coordinating Center

Partner Relations

Effingerstrasse 33

3008 Bern

E-mail: partnerrelations@spog.ch

Phone: +41 31 389 91 89